Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, are pleased to announce they have entered into a research collaboration to combine Avacta’s Affimer protein platform with OncoSec’s gene delivery technology ImmunoPulse®.
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug conjugates, has concluded successfully.
Explore strategies for improving recombinant adeno-associated virus production in transient HEK293 suspension cultures while maintaining vector quality and supporting scalable viral vector manufacturing.
Discover how tissue-resident memory T cells develop within the respiratory tract and how these findings are advancing respiratory virus immunity, vaccine research, and high-throughput immune profiling.
Explore emerging mechanisms of immune checkpoint inhibitor resistance in hepatocellular carcinoma (HCC) and how combination immunotherapy strategies may improve antitumor immune responses and patient-specific treatment approaches.
Sino Biological’s trial program enables qualified customers to evaluate SuperNuclease Pro in their specific bioprocessing applications, facilitating faster technology assessment and informed decision-making during process development
Resipher measures cellular respiration (OCR) continuously in standard 96-well plates inside your incubator, for days to weeks. No media swaps, dyes, or transfers. A live-cell functional readout for drug safety, metabolism, and mitochondrial health.
